Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin monotherapy in Chinese adults with type 2 diabetes mellitus inadequately controlled with diet and exercise
CTR20181103Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sotagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Oct 2018; status: terminated.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20181103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181103.